대한한의학회지 (The Journal of Korean Medicine)

  • 제30권3호
  • /
  • Pages.86-97
  • /
  • 2009
  • /
  • 1010-0695(pISSN)
  • /
  • 2288-3339(eISSN)
대한한의학회 (The Society of Korean Medicine)
권호 표지

Experimental Study on the Effects of GamiSamgieum (SGMX) on Hyperlipidemia

  • Kim, Hun (Department of Internal Medicine, College of Oriental Medicine, Daejeon University) ;
  • An, Joung-Jo (Department of Internal Medicine, College of Oriental Medicine, Daejeon University) ;
  • Jo, Hyun-Kyung (Department of Internal Medicine, College of Oriental Medicine, Daejeon University) ;
  • Yoo, Ho-Rhyong (Department of Internal Medicine, College of Oriental Medicine, Daejeon University) ;
  • Seol, In-Chan (Department of Internal Medicine, College of Oriental Medicine, Daejeon University) ;
  • Kim, Yoon-Sik (Department of Internal Medicine, College of Oriental Medicine, Daejeon University)
  • 발행 : 2009.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : This study was aimed to investigate the effects of GamiSamgieum (SGMX) on hyperlipidemia using an animal model. Additionally, the underlying mechanisms were investigated by determination of gene expressions related with lipid metabolism. Methods : Forty mice were selected for use in this experiment, and then divided into five groups; Naive, Induced, SGMX 100, SGMX 200, and Lovastatin group as positive control with 8 mice each, and their blood was collected for analysis of blood and serum parameters. Results : Administration of SGMX significantly inhibited the increase of liver weight and the macrovacuolar cytoplasmic alterations in histopathologic finding. SGMX administration significantly protected the liver from pathologic elevation of AST and ALT and from lipid peroxidation. SGMX administration significantly lowered total cholesterol levels and TG, and partially upregulated the gene expression of LCAT, CYP7A1 and LDL-R receptor. Conclusion : SGMX is suggested to possess hypolipidemic effect, and thus could be a potential candidate for herbal hypolipidemic via further studies.

키워드

참고문헌

  1. Jain KS, Kathiravan MK, Somani RS, Shishoo CJ. The biology and chemistry of hyperlipidemia. Bioorg Med Chem. 2007;15(14):4674-99. https://doi.org/10.1016/j.bmc.2007.04.031
  2. Kratz M. Dietary cholesterol, atherosclerosis and coronary heart disease. Handb Exp Pharmacol. 2005;1(170):195-213.
  3. Malloy MJ, Kane JP. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med. 2001;47:111-36.
  4. Fowler SB, Kelly M, Ruh D, Johnson-Wells D. Management of lipid disorders for stroke prevention. J Neurosci Nurs. 2006;38:282-7. https://doi.org/10.1097/01376517-200609000-00003
  5. Chapman MJ. The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development. Curr Med Res Opin. 2005; 21(Suppl 6):S17-22.
  6. Havel RJ, Rappaport E. Management of primary hyper-lipidemia. N Engl J Med. 1995;332:14491-9.
  7. Wierzbicki AS, Mikhailidis DP, Wray R. Drug treatment of combined hyperlipidemia. Am J Cardiovasc Drugs. 2001;1(5):327-36. https://doi.org/10.2165/00129784-200101050-00003
  8. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol. 1998 Aug 27;82(4B):3J-10J.
  9. Steinmetz KL, Schonder KS. Colesevelam: potential uses for the newest bile resin. Cardiovasc Drug Rev. 2005 Spring;23 (1):15-30. https://doi.org/10.1111/j.1527-3466.2005.tb00154.x
  10. Ahmed SM, Clasen ME, Donnelly JE. Management of dyslipidemia in adults. Am Fam Physician. 1998 May 1;57(9):2192-204,
  11. Gupta RS, Pramod Kumar, Anita Sharma, Bharadwaj TN, Dixit VP. Hypercholesterolemic activity of Marsilea minuta in gerbils. Fitoterapia 2000;71:113-7 https://doi.org/10.1016/S0367-326X(99)00140-9
  12. Shin WT, Heo JE, Kim TH, Hong SH, Kwon OS, Kim KT, et al. Clinical effect of Dodam-tang on hyperlipidemia patients. The journal of Korean Internal medicine. 2007;fal:113-8.,Korean.
  13. J. Folch, M. A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497-509.
  14. Elpers M. Common obstacles in lipid management. Crit Care Nurs Clin North Am. 2008;20(3):287-95. https://doi.org/10.1016/j.ccell.2008.03.003
  15. Turkoski BB. An ounce of prevention. Drugs used to treat hyperlipidemia. Orthop Nurs. 2004;23(1):58-61. https://doi.org/10.1097/00006416-200401000-00016
  16. Song YN, Kwon SU, Sung J, Ebrahim S, Smith GD, SW S, at al. Different risk factor profiles between subtypes of ischemic stroke. A casecontrol study in Korean men. Eur J Epidemiol. 2005;20(7):605-12. https://doi.org/10.1007/s10654-005-6831-5
  17. Fernando DB, Carla DB, Marcelo C, Mario JY, Frunchart JC, Graciela RC. VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein. Clinica Chemica Acta. 1998;269:107-24. https://doi.org/10.1016/S0009-8981(97)00193-9
  18. Sirtori CR, Fumagalli R. LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. A lesson from cholesterol turnover studies and others. Atherosclerosis. 2006;186(1) :1-11. https://doi.org/10.1016/j.atherosclerosis.2005.10.024
  19. Aronow WS. Management of hyperlipidemia with statins in the older patient. Clin Interv Aging. 2006;1(4):433-8. https://doi.org/10.2147/ciia.2006.1.4.433
  20. Viljoen A. New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease. Recent Patents Cardiovasc Drug Discov. 2008;3(2):84-91. https://doi.org/10.2174/157489008784705313
  21. Pollex RL, Joy TR, Hegele RA. Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs.2008;13(2):363-81. https://doi.org/10.1517/14728214.13.2.363
  22. Lim SM, An JJ, Choi Y, Oh BR, You HR, Kim YS, et al. The study on effects of Samgiyeum and Tongbiyeum on thrombosis and brain damage. Korean J. Orient. Int. Med. 2002;23(4):617-29.
  23. An JJ, Lim SM, Cho HG, Kim MS, You BC, Kim YJ, et al. Study on the Toxicity of Tongbiyeum in rats. Korean J. Orient. Int. Med. 2002; 23(4):607-16.
  24. Zambon D, Ros E, Rodriguez VC, Laguna JC, Vazquez M, Sanllehy C, et al. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism. 1999;48(1):47-54. https://doi.org/10.1016/S0026-0495(99)90009-4
  25. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988;Nov 11;62 (15):10J-15J. https://doi.org/10.1016/0002-9149(88)90002-1
  26. Sandhya VG, Rajamohan T. Comparative evaluation of the hypolipidemic effects of coconut water and lovastatin in rats fed fat-cholesterol enriched diet. Food Chem Toxicol. 2008;46(12):3586-92. https://doi.org/10.1016/j.fct.2008.08.030
  27. Bruce DR. ACAT inhibitors: evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents DDT 1998;3(1):19-25. https://doi.org/10.1016/S1359-6446(97)01123-9
  28. Santamarina FS, Lambert G, Hoeg JM. Lecithincholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol. 2000;11(3):267-75. https://doi.org/10.1097/00041433-200006000-00007
  29. Chawla A, Saez E, Evans RM. “Don’t know much bile-ology”. Cell. 2000;103(1):1-4. https://doi.org/10.1016/S0092-8674(00)00097-0
  30. Sekiya M, Hiraishi A, Touyama M, Sakamoto K. Oxidative stress induced lipid accumulation via SREBP1c activation in HepG2 cells. Biochem Biophys Res Commun. 2008;375(4):602-7. https://doi.org/10.1016/j.bbrc.2008.08.068
  31. Kim MS, Kwon DY, Cho HJ, Lee MS. Protective effects of Korean herbal remedy against oxidative stress in cardiomyocytes. Phytother Res. 2006;20(3):235-6. https://doi.org/10.1002/ptr.1837
  32. Kim GY, Seo IB. Effects of SemyungGamiTang on the blood lipid in experimentally induced hyperlipidemic rabbits. J. Korean Oriental Med. 2000;20(4):69-81. Korean.